Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Renasant Bio
United States
- Berkeley, California
- 11/07/2025
- Seed
- $54,500,000
Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression.
- Industry Biotechnology Research
- Website https://www.renasantbio.com/
- LinkedIn https://www.linkedin.com/company/renasant-bio/
Related People
Emily ConleyFounder
United States -
San Francisco Bay Area
Strategic biotech executive with a proven track record of advancing disruptive platforms in drug
development. Architect of visionary partnerships across pharma and biotech (big cap to small cap).
Expert at scaling: joined 23andMe at 30 employees and helped grow it to 600+. Deep scientific
expertise with 35 academic publications. Industry thought-leader with national TV appearances.
Named one of the “20 under 40” leaders in biotech. Multiple board appointments. Big-picture thinker,
who is passionate about healthcare with a gift for inspiring teams and helping companies thrive.
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)